

VITA LIFE SCIENCES LIMITED (ABN: 35 003 190 421)

APPENDIX 4D- Half Year Report Period Ended 30 June 2025

1. Reporting Period

This announcement is made pursuant to Listing rule 4.2A.3 as approved by the Board of Vita Life Sciences Ltd (ASX Code: VLS).

The information contained in this report is to be read in conjunction with Vita Life Sciences Limited's Half Year June 2025 Financial Report, the 2024 Annual Report and any announcements to the market by the Company during the half year ended 30 June 2025 (current period). The Previous Corresponding Period (PCP) was the half-year ended 30 June 2024.

2. Results for announcement to the market

		Percentage Change* %	2025 A\$'000	2024 A\$'000
Revenue	Up	15.4	45,544	39,451
Profit before income tax	Up	12.7	6,782	6,017
Net profit after tax	Up	12.2	4,822	4,297
Net profit attributable to members	Up	12.2	4,840	4,314

*Based on Previous Corresponding Period (PCP)

Dividend			Amount per security	Franked amount per security
Interim 2025 dividend	Ex-Date	19 September 2025		
	Record Date	22 September 2025		
	Payment Date	3 October 2025	4.5 cents	4.5 cents
Final 2024 dividend	Paid	11 April 2025	6.5 cents	6.5 cents

Commentaries of the above results can be found in the attached half year directors' and consolidated financial report for the period ended 30 June 2025.

3. Net tangible assets

	30 June 2025	30 June 2024
Net Tangible Assets per security	\$0.89	\$0.82

4. **There were no entities over which control has been gained nor lost during the period.**
5. **Dividends**

A fully franked dividend of 6.50 cents per share amounting to \$3.6 million was paid on 11 April 2025 in relation to the year ended 31 December 2024.

Directors have declared the payment of a fully franked interim dividend for the six months to 30 June 2025 of 4.5 cents per ordinary share, an increase of 1.0 cent per share on the PCP, as disclosed above. The Company's dividend reinvestment plan (DRP) has been suspended and shall not apply to the above dividends.
6. **Details of associates and joint venture entities- Nil**
7. **For foreign entities, the International Financial Reporting Standard–IFRS, were used in compiling these reports.**
8. **The attached financial statements have been reviewed by the Independent Auditor and, a copy of the Independent Auditor's Review Report is attached to the Half Year Financial Report.**



Half Year Report

30 June 2025





Contents

Directors' Report –	3
Auditor's Independence Declaration –	5
Condensed Consolidated Statement of Comprehensive Income –	7
Condensed Consolidated Statement of Financial Position –	8
Condensed Consolidated Statement of Cash Flows –	9
Condensed Consolidated Statement of Changes in Equity –	10
Notes to the Condensed Consolidated Financial Statements –	12
Directors' Declaration –	17
Independent Auditor's Review Report –	18
General information –	20

Directors' Report



THE DIRECTORS OF VITA LIFE SCIENCES LIMITED (“COMPANY” OR “VITA LIFE SCIENCES”) SUBMIT THEIR REPORT TOGETHER WITH THE FINANCIAL REPORT FOR VITA LIFE SCIENCES AND ITS CONTROLLED ENTITIES FOR THE HALF-YEAR ENDED 30 JUNE 2025

DIRECTORS

The names of the Company's directors in office throughout and since the end of the last financial period are set out below.

Mr Henry G Townsing	Chairman
Mr Andrew O'Keefe	Managing Director
Mr Peter Osborne	Non-Executive Director
Mr Jack Teoh	Non-Executive Director

All directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

Principal Activities

During the period in review, the principal continuing activities of the consolidated entity consisted of formulating, packaging, sales and distribution of vitamins and supplements.

OPERATING AND FINANCIAL REVIEW

The Group delivered a strong performance for the six months ended 30 June 2025, with revenue increasing by 14% to \$45.5 million and profit before income tax rising by 13% to \$6.8 million compared to the previous corresponding period (PCP).

Key highlights:

- **Revenue Growth:** Broad based growth across core markets, supported by strong performances across all major channels and positive consumer sentiment.
- **Market Focus:** Continued expansion in Australia, Malaysia, Singapore and China, with targeted initiatives to strengthen market penetration.
- **Marketing and Brand Investment:** Advertising and promotional expenditure increased by 26% on PCP, driving brand visibility and consumer engagement.
- **Financial Position:** Balance sheet remains robust with equity of \$52.6 million and cash reserves of \$29.4 million, with no bank borrowings.
- **Dividend:** A fully franked interim dividend of 4.5 cents per share was declared for the period, representing an increase of 1.0 cent per share on PCP.

PERFORMANCE BY MARKET

Australia

Domestic revenue rose 8% to \$19.6 million, driven by strong growth in both health food stores and pharmacy channels. EBIT declined by 2% versus PCP, reflecting higher operating expenses and increased trade investment. Customer acquisition continues to grow, particularly in the domestic pharmacy segment. Herbs of Gold has now established itself as a recognised brand in selected Australian pharmacies, enhancing its accessibility and market presence.

Malaysia / Singapore

Revenue grew by 54% to \$21.9 million, underpinned by exceptional performance in Malaysia and solid growth

in Singapore. EBIT increased by 87% versus PCP. This was supported by stronger retailer partnerships, intensified marketing campaigns, expanded product ranges in key chain pharmacies, and enhanced trade marketing activities. High levels of in-market consumer events have strengthened brand loyalty and contributed to robust sales momentum.

Other Markets – China and Vietnam

In China, export sales declined 45% versus PCP, impacted by the transition to a new exclusive distributor early in the year and a slower-than-anticipated first-quarter handover. Performance has improved in recent months as consumer demand recovers across major e-commerce platforms.

In Vietnam, sales were marginally lower than PCP due to softer offtake for VitaHealth and Herbs of Gold. To support growth in the second half, a broader channel strategy is being implemented, including the appointment of a new exclusive distributor for Herbs of Gold in the pharmacy and e-commerce channels, alongside continued collaboration with ConCung in the Mum and Baby segment.

OUTLOOK

The Board is encouraged by the Group's first-half performance, particularly the strength in Australia, Malaysia and Singapore, and expects this momentum to be maintained into the second half. While China remains a challenging market, recent improvements provide a cautiously optimistic outlook. The Group remains committed to delivering full-year revenue and profit before tax growth over PCP, with further guidance to be provided in the fourth quarter.

ROUNDING OFF

Vita Life Sciences is a company of the kind referred to in ASIC Legislative Instrument 2016/191 dated 24 March 2016 and, in accordance with that Instrument, amounts in the financial report and directors' report have been rounded off to the nearest thousand dollars, unless otherwise indicated.

AUDITOR'S INDEPENDENCE DECLARATION

The Directors have received an Independence Declaration from the external auditor, Nexia Sydney Audit Pty Ltd. A copy of this Declaration follows the Directors Report.

This Directors' report is signed in accordance with a resolution of the Board of Directors made pursuant to s.306(3) of the Corporations Act 2001.



Andrew O'Keefe
Managing Director
Sydney, 25 August 2025

To the Board of Directors of Vita Life Sciences Limited

**LEAD AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C
OF THE CORPORATIONS ACT 2001**

As lead audit director for the review of the condensed consolidated financial statements of Vita Life Sciences Limited for the half-year ended 30 June 2025, I declare that, to the best of my knowledge and belief, there has been no contravention of:

- a) the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- b) any applicable code of professional conduct in relation to the review.

Yours sincerely,



Nexia Sydney Audit Pty Limited



Stephen Fisher
Director

Dated: 25 August 2025

June 2025
**Financial
Report**

For personal use only



CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE HALF YEAR ENDED	Notes	Consolidated	
		30 June 2025 \$'000	30 June 2024 \$'000
Sale of goods		45,544	39,451
Cost of sales		(18,154)	(16,466)
Gross profit		27,390	22,985
Other income		21	18
Distribution expenses		(3,860)	(2,982)
Marketing expenses		(4,475)	(3,561)
Occupancy expenses		(492)	(497)
Administrative expenses		(11,613)	(10,047)
Other expenses		(453)	(326)
Profit before interest and taxes	3	6,518	5,590
Finance income		462	528
Finance costs		(198)	(101)
Profit before income tax	3	6,782	6,017
Income tax expense		(1,960)	(1,720)
Net profit for the half year	3	4,822	4,297
Other comprehensive income after income tax			
Items that will be reclassified subsequently to profit or loss when specific conditions are met:			
Exchange differences on translating foreign controlled entities		235	199
Other comprehensive income for the half year, net of income tax		235	199
Total comprehensive income for half year		5,057	4,496
Net profit/(loss) for the half year attributable to:			
Non-controlling interest		(18)	(17)
Members of the parent		4,840	4,314
		4,822	4,297
Total comprehensive income attributable to:			
Non-controlling interest		(18)	(17)
Members of the parent		5,075	4,513
		5,057	4,496
Earnings per share (cents per share)			
- basic earnings per share	5	8.61	7.84
- diluted earnings per share	5	8.61	7.84

THE CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME SHOULD BE READ IN CONJUNCTION WITH THE ACCOMPANYING NOTES TO THE HALF YEAR REPORT.

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT	Notes	Consolidated	
		30 June 2025 \$'000	31 Dec 2024 \$'000
ASSETS			
Current Assets			
Cash and cash equivalents		29,396	28,601
Trade and other receivables		13,407	11,999
Inventories		14,692	16,599
Other assets		1,722	1,699
Total Current Assets		59,217	58,898
Non Current Assets			
Property, plant and equipment		12,296	10,329
Intangible assets		31	50
Deferred tax assets		3,101	2,615
Total Non Current Assets		15,428	12,994
Total Assets		74,645	71,892
LIABILITIES			
Current Liabilities			
Trade and other payables		10,778	11,745
Current tax liability		1,401	581
Employee entitlements		2,200	1,840
Contract return Liability		5,277	4,805
Lease Liability		488	303
Total Current Liabilities		20,144	19,274
Non Current Liabilities			
Employee Entitlements		127	121
Lease Liability		1,757	214
Total Non Current Liabilities		1,884	335
Total Liabilities		22,028	19,609
Net Assets		52,617	52,283
EQUITY			
Contributed equity	6	43,794	45,030
Accumulated profits		2,080	846
Employee share based payments reserve		2,872	2,753
Share options reserve		992	992
Revaluation Reserve		859	859
Foreign currency translation reserve		2,109	1,874
Parent entity interest		52,706	52,354
Non-controlling interest		(89)	(71)
Total Equity		52,617	52,283

THE CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION SHOULD BE READ IN CONJUNCTION WITH THE ACCOMPANYING NOTES TO THE HALF YEAR REPORT.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE HALF YEAR ENDED	Notes	Consolidated	
		30 June 2025 \$'000	30 June 2024 \$'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		46,985	40,390
Payments to suppliers and employees		(39,513)	(36,595)
Income tax paid		(1,140)	(1,588)
Interest received		462	528
Lease interest and bank charges		(198)	(78)
Net cash flows provided by operating activities		6,596	2,657
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		(730)	(8)
Net cash flows used in investing activities		(730)	(8)
CASH FLOWS FROM FINANCING ACTIVITIES			
Payment of leases		(292)	(158)
Dividends Paid		(3,606)	(3,263)
Repayment of LTIP shares loans		-	3,856
Share buy back		(1,236)	(2)
Net cash flows provided by/(used in) financing activities		(5,134)	433
Net increase in cash and cash equivalents		732	3,082
Net foreign exchange differences		63	36
Cash and cash equivalents at beginning of the period		28,601	24,630
Cash and cash equivalents at end of the period		29,396	27,748

THE CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS SHOULD BE READ IN CONJUNCTION WITH THE ACCOMPANYING NOTES TO THE HALF YEAR REPORT.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE HALF YEAR ENDED 30 JUNE 2025		Contributed Equity	Employee Share Based Payments Reserve	Share Options Reserve	Revaluation Reserve	Accumulated Losses	Foreign Currency Translation Reserve	Attributable to Equity Holders of Parent	Non- controlling Interest	Total
	Note	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
Balance at 1 January 2025		45,030	2,753	992	859	846	1,874	52,354	(71)	52,283
Comprehensive income										
Profit attributable to members of parent entity		-	-	-	-	4,840	-	4,840	(18)	4,822
Other comprehensive income for the period		-	-	-	-	-	235	235	-	235
Total comprehensive income for the period		-	-	-	-	4,840	235	5,075	(18)	5,057
Transactions with owners, in their capacity as owners										
Loan Repayment on shares issued	6	-	-	-	-	-	-	-	-	-
Shares bought back		(1,236)	-	-	-	-	-	(1,236)	-	(1,236)
Employee share based expense		-	119	-	-	-	-	119	-	119
Dividends paid	7	-	-	-	-	(3,606)	-	(3,606)	-	(3,606)
Total transactions with owners		(1,236)	119	-	-	(3,606)	-	(4,723)	-	(4,723)
Balance at 30 June 2025		43,794	2,872	992	859	2,080	2,109	52,706	(89)	52,617

THE CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY SHOULD BE READ IN CONJUNCTION WITH THE ACCOMPANYING NOTES TO THE HALF YEAR REPORT.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (CONTINUED)

FOR THE HALF YEAR ENDED 30 JUNE 2024	Note	Contributed Equity	Employee Share Based Payments Reserve	Share Options Reserve	Revaluation Reserve	Accumulated Losses	Foreign Currency Translation Reserve	Attributable to Equity Holders of Parent	Non-controlling Interest	Total
		\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
Balance at 1 January 2024		42,567	2,318	992	859	(2,769)	(570)	43,397	(66)	43,331
Comprehensive income										
Profit attributable to members of parent entity		-	-	-	-	4,314	-	4,314	(17)	4,297
Other comprehensive income for the period		-	-	-	-	-	199	199	-	199
Total comprehensive income for the period		-	-	-	-	4,314	199	4,513	(17)	4,496
Transactions with owners, in their capacity as owners										
Loan Repayment on shares issued	6	3,856	-	-	-	-	-	3,856	-	3,856
Shares bought back		(2)	-	-	-	-	-	(2)	-	(2)
Employee share based expense		-	285	-	-	-	-	285	-	285
Dividends paid	7	-	-	-	-	(3,263)	-	(3,263)	-	(3,263)
Total transactions with owners		3,854	285	-	-	(3,263)	-	876	-	876
Balance at 30 June 2024		46,421	2,603	992	859	(1,718)	(371)	48,786	(83)	48,703

THE CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY SHOULD BE READ IN CONJUNCTION WITH THE ACCOMPANYING NOTES TO THE HALF YEAR REPORT.

For personal use only

Notes to the condensed consolidated

Financial Statements



NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF YEAR ENDED 30 JUNE 2025

1. CORPORATE INFORMATION

The Half Year financial report of Vita Life Sciences Limited ("Vita Life Sciences") and its controlled entities ("the Group") for the half-year ended 30 June 2025 was authorised for issue by a resolution of the directors on the date of this report.

Vita Life Sciences is a Company limited by shares, incorporated and domiciled in Australia, whose shares are publicly traded on the Australian Securities Exchange ("ASX").

The nature of the operations and principal activities of the Group are described in the Directors' Report.

2. BASIS OF PREPARATION

These general purpose condensed consolidated financial statements for the half-year reporting period ended 30 June 2025, have been prepared in accordance with the requirements of the Corporations Act 2001, and Australian Accounting Standard AASB 134 "Interim Financial Reporting." The Group is a for-profit entity for financial reporting purposes under Australian Accounting Standards.

This interim financial report is intended to provide users with an update on the latest annual financial statements of Vita Life Sciences Limited. As such, it does not contain information that represents relatively insignificant changes occurring during the half-year within the Group. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of the Group for the year ended 31 December 2024, together with any public announcements made during the following half-year.

The same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent annual financial statements, except for the effects of applying newly effective accounting standards as outline below.

The half-yearly condensed consolidated financial statements have been prepared on a historical cost basis.

New and amended accounting standards and interpretations adopted by the Group

The Group has adopted all of the new or amended Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (AASB) that are mandatory for the current period.

New accounting standards and interpretations not yet adopted

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

3. SEGMENT REPORTING

The Group has a single business; development and sale of complementary medicine including vitamins, minerals and food supplements (VMS) and organised as two key operating segments. The two segments are managed by geographical market with information used by the Managing Director, the Group's Chief Operating Decision Maker (CODM), Board members and the management team.

The two segments are, VMS Operational and VMS Investments.

VMS Operational is characterised by well established Group brands/ markets with high brand recognition and mature operations.

VMS Investment is characterised by Group brands/ markets being relative new to a geographic market with low brand recognition. These developing businesses require higher ongoing investment, sourced from within the Group to fund operations.

The Managing Director, Board and management team review sales performance and other financial metrics.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF YEAR ENDED 30 JUNE 2025

3. SEGMENT REPORTING (CONTINUED)

	VMS Operational		VMS Investment		Corporate	Total \$'000
	Australia	Malaysia & Singapore	China & Vietnam	Others		
	\$'000	\$'000	\$'000	\$'000	\$'000	
Half Year ended 30 June 2025						
Revenue						
Sales to external customers	19,576	21,914	4,054	-	-	45,544
Segment results						
Earnings before interest and tax	2,171	4,998	(144)	(23)	(484)	6,518
Net interest and bank charges						264
Profit before income tax						6,782
Income tax expense						(1,960)
Net profit for the period						4,822
Property Plant & Equipment	2,265	9,938	93	-	-	12,296

	VMS Operational		VMS Investment		Corporate	Total \$'000
	Australia	Malaysia & Singapore	China & Vietnam	Others		
	\$'000	\$'000	\$'000	\$'000	\$'000	
Half Year ended 30 June 2024						
Revenue						
Sales to external customers	18,182	14,192	7,077	-	-	39,451
Segment results						
Earnings before interest and tax	2,226	2,674	1,565	(206)	(669)	5,590
Net interest and bank charges						427
Profit before income tax						6,017
Income tax expense						(1,720)
Net profit for the period						4,297
Property Plant & Equipment						
	121	8,891	170	-	-	9,182

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF YEAR ENDED 30 JUNE 2025

4. NET TANGIBLE ASSETS

	CONSOLIDATED	
	30 June 2025 \$	30 June 2024 \$
Net assets per share	0.94	0.86
Net tangible assets per share	0.89	0.82
	Number	Number
Number of ordinary shares for net assets per share	55,909,936	56,525,733

5. EARNINGS PER SHARE

	2025 \$'000	2024 \$'000
Net profit attributable to equity holders from continuing operations	4,822	4,297
Loss attributable to non-controlling interest	18	17
Earnings used to calculate basic and dilutive earnings per share	4,840	4,314
	Number	Number
Weighted average number of ordinary shares for basic earnings per share	56,247,034	54,995,472
Adjusted weighted average number of ordinary shares for diluted earnings per share. As at 30 June 2025, all the LTIP shares were non-dilutive for the purpose of this calculation as they were out-of-the money. As at 30 June 2024, all the LTIP shares were non-dilutive for the purpose of this calculation as they were out-of-the money.	56,247,034	54,995,472

6. ISSUED CAPITAL

	2025 Number	2024 Number	2025 \$	2024 \$
Issued and paid up capital				
Ordinary shares	55,909,936	56,399,258	43,793,869	46,420,724
Ordinary shares				
Balance at beginning of the period	56,560,582	56,400,137	45,030,261	42,566,853
Share buy back (a)	(650,646)	(879)	(1,236,392)	(2,129)
Payment of loan for shares to employee/ directors (b)	-	-	-	3,856,000
Balance at end of the period	55,909,936	56,399,258	43,793,869	46,420,724

- a) A total of 650,646 (2024: 879) ordinary shares were bought back for the half year ended 30 June 2025 at a total cost of \$1,236,392 (2024: \$2,129).

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF YEAR ENDED 30 JUNE 2025

- b) Employees and directors repaid \$Nil (2024: \$3,856,000) loan under the LTIP shares scheme, during the half year ended 30 June 2025.

For the half year ended 30 June 2025, the Company recognised net expense of \$119,826 (2024: \$285,354) in the income statement with a corresponding increase in employee share based payment reserve (2024: increase in employee share based payment reserve).

- c) In the half year ended 30 June 2024, the Company approved loans to the Managing Director, Mr Andrew O'Keefe totaling \$690,000 in order for Mr O'Keefe to purchase a total of 300,000 new shares under the Company's Long Term Incentive Plan (LTIP). These shares were however issued after 30 June 2024.

The cost of the equity-settled transactions is measured by reference to the fair value of the equity instruments at the date at which they were granted. The cost is recognised in the income statement together with a corresponding increase in equity, over the period in which the performance and / or service conditions are fulfilled (the vesting period), ending on the date on which the employees become fully entitled to the award (the vesting date).

7. DIVIDEND

A fully franked dividend of 6.50 cents per share amounting to \$3,605,038 (2024: 6.00 cents per share franked totalling \$3,263,141) was paid on 11 April 2025 in relation to the year ended 31 December 2024.

A fully franked interim dividend of 4.50 cents per share, has been declared and will be paid on 3 October 2025. The record date for the interim dividend is 22 September 2025.

8. COMMITMENTS

The Group has no capital commitments as at 30 June 2025 (2024: Nil).

9. EVENTS AFTER THE BALANCE SHEET DATE

Apart from the dividend proposed in Note 7, no matters or circumstances have arisen since the end of the financial period which significantly affected or could significantly affect the operations of the economic entity, the results of those operations or the state of affairs of the economic entity in future financial years.

10. CONTINGENT ASSETS AND LIABILITIES

The Group has no contingent assets or liabilities as at 30 June 2025 (2024: Nil).

11. RELATED PARTIES DISCLOSURES

Transactions with related parties

The following table provides the total amount of transactions that were entered into with related parties for the relevant financial period.

	30 June 2025 \$'000	30 June 2024 \$'000
Land Real Pty Ltd (i)	1	1
Atlas Horizon Pty Ltd (ii)	1	-
Luke O'Keefe (iii)	-	1

- (i) Land Real Pty Ltd, a company in which Mr. Henry Townsing is a Director and therefore a related party, was paid storage fees during the financial period.
- (ii) Atlas Horizon Pty Ltd, a company controlled by a party related to Mr Henry Townsing and, therefore a related party, was paid a fee for consulting services during the financial period.
- (iii) Luke O'Keefe, a person related to Mr. Andrew O'Keefe was paid photography services during the financial period.

In the opinion of the directors of Vita Life Sciences Limited:

- (a) The financial statements and notes of the consolidated entity are in accordance with the *Corporations Act 2001*, including:
 - (i) giving a true and fair view of the consolidated entity's financial position as at 30 June 2025 and its performance for the half-year ended on that date; and
 - (ii) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the Corporations Regulations 2001.
- (b) There are reasonable grounds to believe that the consolidated entity will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the directors made pursuant to s.303(5) of the *Corporations Act 2001*:



Andrew O'Keefe
Managing Director
Sydney, 25 August 2025

INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of Vita Life Sciences Limited

Report on the Half-Year Financial Report

Conclusion

We have reviewed the half-year financial report of Vita Life Sciences Limited its subsidiaries ("the Group"), which comprises the condensed consolidated statement of financial position as at 30 June 2025, the condensed consolidated statement of comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the half-year ended on that date, a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

- (a) giving a true and fair view of the Group's financial position as at 30 June 2025 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's review report.

Responsibility of the Directors for the Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 30 June 2025 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Nexia Sydney Audit Pty Limited



Stephen Fisher
Director

Dated: 25 August 2025

Board of Directors**Henry Townsing**

Chairman

Non-Executive Director

Andrew O'Keefe

Managing Director

Peter Osborne

Non-Executive Director

Jack Teoh

Non-Executive Director

Company Secretary**Chin L Khoo**

Company Secretary

Registered Office**Australian Head Office**

Suite 802, Level 8

1-5 Chalmers Crescent

Mascot NSW 2020

Australia

T: 61 2 9545 2633

F: 61 2 9545 1311

Asian Regional Office

23, Jalan Jurunilai U1/20

Hicom-Glenmarie Industrial Park

40150 Shah Alam, Selangor

Malaysia

T: 60 3 5569 6323

F: 60 3 5569 2393

Securities Exchange Listing

The ordinary shares of Vita Life Sciences Limited are listed on the Australian Securities Exchange Ltd

ASX Code: VLS

Auditor

Nexia Sydney Audit Pty Limited

Level 22, 2 Market Street

Sydney NSW 2000

Banker

National Australia Bank Limited

Westpac Banking Corporation

Solicitor

K & L Gates LLP

Level 25, 525 Collins Street

Melbourne VIC 3000

Share Registry

Automic

Level 5, 126 Phillip Street

Sydney NSW 2000

T: 1300 288 664

T: 61 2 8072 1400

Change of Address

Shareholders who have changed address should advise our share registry in writing.

Annual Report Mailing

Shareholders who do not want the annual report or who are receiving more than one copy should advise the share registry in writing.

Vita Life Sciences Website

Vita Life Sciences has a website containing information about the Company, its Business and Products.

www.vitalifesciences.com

For personal use only



Vita Life Sciences Limited

ACN 003 190 421
ABN 35 003 190 421

enquiries@vitalifesciences.com
vitalifesciences.com

**Registered Office
Australian Head Office**

Suite 802, Level 8
1-5 Chalmers Crescent
Mascot NSW 2020
Australia
T: 61 2 9545 2633
F: 61 2 9545 1311

Asian Regional Office

No. 23, Jalan Jurunilai U1/20
Hicom Glenmarie Industrial Park
Seksyen U1
40150 Shah Alam
Selangor Darul Ehsan
Malaysia
T: 60 3 5569 6323
F: 60 3 5569 2393